Company Reports Q1 Revenue of $116.3M, Exceeding Expectations
Reports Q1 revenue $116.3M, consensus $115.74M. "In Q1 2026, we achieved 12% constant currency revenue growth and 26% adjusted EBITDA growth, reflecting continued execution of our strategy to deliver long-term, profitable performance with an expanding and clinically differentiated product portfolio. On a constant currency basis, Q1 year-over-year stent grafts, On-X, and preservation services grew 10%, 17%, and 23%, respectively," said CEO Pat Mackin. "We have since exercised our option to acquire Endospan and expect the acquisition to close in the Q2, subject to customary closing conditions...While our first quarter performance fell short of our constant currency expectations due to some transient factors, we are confident that the fundamentals underpinning our strategy remain intact. We are seeing strong reordering behavior within AMDS accounts, which exceeded our expectations and reinforces our conviction in long-term adoption. Meanwhile, On-X continues to take share from both mechanical and bioprosthetic valves as the leading aortic valve on the market for patients under the age of 65."
